<DOC>
	<DOCNO>NCT01126281</DOCNO>
	<brief_summary>The aim study evaluate effect safety Floseal preliminary prospective trial patient undergo acute laparoscopic cholecystectomy acute cholecystitis</brief_summary>
	<brief_title>Efficacy Safety Floseal Haemostasis During Laparoscopic Cholecystectomy Acute Cholecystitis ( GLA )</brief_title>
	<detailed_description />
	<mesh_term>Cholecystitis</mesh_term>
	<mesh_term>Acalculous Cholecystitis</mesh_term>
	<mesh_term>Cholecystitis , Acute</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients age 18 65 Clinical ( pain , fever &gt; 37.5 Â°C , WBC &gt; 10.000 / microL ) , ultrasound evidence cholecystitis Surgical indication laparoscopic cholecystectomy ASA class IIII Informed consent &lt; 72 hour onset symptom Informed consent refusal Choledocholithiasis Pre surgical generalize peritonitis ( clinical evaluation ) ASA class &gt; III Peripheral artery disease Active past history malignant systemic disease Pregnant lactating female Known allergy component Floseal include bovine allergy ( bovine gelatin ) Known drug alcohol abuse Patients know diabetes , chronic renal disease metabolic diseases Patients chronic cortisone treatment 2 year surgery Patients chronic use platelet inhibitor Aspirin , Plavix , NSAID 's etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>